Literature DB >> 9868423

Antifungal agents. Part I. Amphotericin B preparations and flucytosine.

R Patel1.   

Abstract

Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid formulations, including amphotericin B lipid complex, amphotericin B cholesteryl sulfate, and liposomal amphotericin B, have been introduced. The pharmacologic properties, main indications, recommended dosages, related costs, and adverse effects of these various preparations are summarized in this review. Orally administered flucytosine is useful in certain infections, particularly cryptococcal meningitis, but it should be used with caution in patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868423     DOI: 10.4065/73.12.1205

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  17 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.

Authors:  A Adedoyin; C E Swenson; L E Bolcsak; A Hellmann; D Radowska; G Horwith; A S Janoff; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 5.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Flucytosine-induced colitis.

Authors:  Muhammad Adnan Sohail; Muhammad Adnan Sohail; Umaira Ikram
Journal:  BMJ Case Rep       Date:  2014-04-28

7.  Candida parapsilosis peritonitis in patients on CAPD.

Authors:  Charoen Kaitwatcharachai
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

Review 8.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

10.  Comparative pharmacokinetics of continuous and conventional intrathecal amphotericin B in rabbits.

Authors:  Min Fang; Tian Ming Lü; An De Ma; Li Wang; Guo Liang Li; Ai Zhu Qiu; Zhi Yong Pan; Yuan Yuan Wang; Xiao Jia Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.